The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Targeting Glycosylation: A New Road for Cancer Drug Discovery
Open accessAbstract
Cancer is a deadly disease that encompasses numerous cellular modifications. Among them, alterations in glycosylation are a proven reliable hallmark of cancer, with most biomarkers used in the clinic detecting cancer-associated glycans. Despite their clear potential as therapy targets, glycans have been overlooked in drug discovery strategies. The complexity associated with the glycosylation process, and lack of specific methodologies to study it, have long hampered progress. However, recent advances in new methodologies, such as glycoengineering of cells and high-throughput screening (HTS), have opened new avenues of discovery. We envision that glycan-based targeting has the potential to start a new era of cancer therapy. In this article, we discuss the promise of cancer-associated glycosylation for the discovery of effective cancer drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Specificity and mechanism of action of some commonly used protein kinase inhibitors
DAVIES, S. P., REDDY, H., CAIVANO, M., & COHEN, P. (2000) · Biochemical Journal · doi:10.1042/bj3510095 · Cited by 3,132
Glycosylation in cancer: mechanisms and clinical implications
Pinho, S. S., & Reis, C. A. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3982 · Cited by 3,083
Self-citationVarki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
Impact of high-throughput screening in biomedical research
Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3368 · Cited by 1,364
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
Kinase-targeted cancer therapies: progress, challenges and future directions
Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,245
Protein Glycosylation in Cancer
Stowell, S. R., Ju, T., & Cummings, R. D. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040438 · Cited by 873
Comparing antibody and small-molecule therapies for cancer
Imai, K., & Takaoka, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1913 · Cited by 792
Posey, A. D., Schwab, R. D., Boesteanu, A. C., Steentoft, C., Mandel, U., Engels, B., Stone, J. D., Madsen, T. D., Schreiber, K., Haines, K. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.014 · Cited by 594
Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading?
Mereiter, S., Balmaña, M., Campos, D., Gomes, J., & Reis, C. A. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.06.006 · Cited by 565
Self-citationCroci, D. O., Cerliani, J. P., Dalotto-Moreno, T., Méndez-Huergo, S. P., Mascanfroni, I. D., Dergan-Dylon, S., Toscano, M. A., Caramelo, J. J., García-Vallejo, J. J., Ouyang, J., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.043 · Cited by 505
The tumour glyco-code as a novel immune checkpoint for immunotherapy
RodrÍguez, E., Schetters, S. T. T., & van Kooyk, Y. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2018.3 · Cited by 473
Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome
Rillahan, C. D., Antonopoulos, A., Lefort, C. T., Sonon, R., Azadi, P., Ley, K., Dell, A., Haslam, S. M., & Paulson, J. C. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.999 · Cited by 447
Precision glycocalyx editing as a strategy for cancer immunotherapy
Xiao, H., Woods, E. C., Vukojicic, P., & Bertozzi, C. R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608069113 · Cited by 440
Lee, H.-H., Wang, Y.-N., Xia, W., Chen, C.-H., Rau, K.-M., Ye, L., Wei, Y., Chou, C.-K., Wang, S.-C., Yan, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.06.008 · Cited by 405
Fluorescence polarization assays in small molecule screening
Lea, W. A., & Simeonov, A. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.537322 · Cited by 379
Increased susceptibility to colitis and colorectal tumors in mice lacking core 3–derived O-glycans
An, G., Wei, B., Xia, B., McDaniel, J. M., Ju, T., Cummings, R. D., Braun, J., & Xia, L. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061929 · Cited by 352
Ten things you should know about protein kinases: IUPHAR R eview 14
Fabbro, D., Cowan‐Jacob, S. W., & Moebitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 347
Immature truncated O-glycophenotype of cancer directly induces oncogenic features
Radhakrishnan, P., Dabelsteen, S., Madsen, F. B., Francavilla, C., Kopp, K. L., Steentoft, C., Vakhrushev, S. Y., Olsen, J. V., Hansen, L., Bennett, E. P., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406619111 · Cited by 313
The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice
Engle, D. D., Tiriac, H., Rivera, K. D., Pommier, A., Whalen, S., Oni, T. E., Alagesan, B., Lee, E. J., Yao, M. A., Lucito, M. S., et al. (2019) · Science · doi:10.1126/science.aaw3145 · Cited by 287
Narimatsu, Y., Joshi, H. J., Nason, R., Van Coillie, J., Karlsson, R., Sun, L., Ye, Z., Chen, Y.-H., Schjoldager, K. T., Steentoft, C., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.05.017 · Cited by 276
Discovery of O- GlcNAc Transferase Inhibitors
Gross, B. J., Kraybill, B. C., & Walker, S. (2005) · Journal of the American Chemical Society · doi:10.1021/ja0555217 · Cited by 248
Glycosylation in cancer: Selected roles in tumour progression, immune modulation and metastasis
Rodrigues, J. G., Balmaña, M., Macedo, J. A., Poças, J., Fernandes, Â., de-Freitas-Junior, J. C. M., Pinho, S. S., Gomes, J., Magalhães, A., Gomes, C., et al. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.03.007 · Cited by 247
Self-citationTargeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates
Sharkey, R. M., & Goldenberg, D. M. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.4.226 · Cited by 242
Fluorescence polarization assays in high-throughput screening and drug discovery: a review
Hall, M. D., Yasgar, A., Peryea, T., Braisted, J. C., Jadhav, A., Simeonov, A., & Coussens, N. P. (2016) · Methods and Applications in Fluorescence · doi:10.1088/2050-6120/4/2/022001 · Cited by 225
High-Throughput Screening: Update on Practices and Success
Fox, S., Farr-Jones, S., Sopchak, L., Boggs, A., Nicely, H. W., Khoury, R., & Biros, M. (2006) · SLAS Discovery · doi:10.1177/1087057106292473 · Cited by 217
Telen, M. J., Wun, T., McCavit, T. L., De Castro, L. M., Krishnamurti, L., Lanzkron, S., Hsu, L. L., Smith, W. R., Rhee, S., Magnani, J. L., et al. (2015) · Blood · doi:10.1182/blood-2014-06-583351 · Cited by 211
Developing inhibitors of glycan processing enzymes as tools for enabling glycobiology
Gloster, T. M., & Vocadlo, D. J. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1029 · Cited by 195
Therapeutic monoclonal antibody N-glycosylation – Structure, function and therapeutic potential
Cymer, F., Beck, H., Rohde, A., & Reusch, D. (2017) · Biologicals · doi:10.1016/j.biologicals.2017.11.001 · Cited by 157
Mechanisms of cancer-associated glycosylation changes
Dall’Olio, F., Malagolini, N., Trinchera, M., & Chiricolo, M. (2011) · Frontiers in bioscience · doi:10.2741/3951 · Cited by 154
Scintillation Proximity Assays in High-Throughput Screening
Glickman, J. F., Schmid, A., & Ferrand, S. (2008) · Assay and Drug Development Technologies · doi:10.1089/adt.2008.135 · Cited by 114
Probing the O-Glycoproteome of Gastric Cancer Cell Lines for Biomarker Discovery*
Campos, D., Freitas, D. P., Gomes, J., Magalhães, A., Steentoft, C., Gomes, C., Vester-Christensen, M. B., Ferreira, J. A., Afonso, L. P., Santos, L. L., et al. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.046862 · Cited by 113
Self-citationComing-of-Age of Antibodies in Cancer Therapeutics
Ayyar, B. V., Arora, S., & O’Kennedy, R. J. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.09.005 · Cited by 110
David, L., Nesland, J. M., Clausen, H., Carneiro, F., & Sobrinho-Simões, M. A. (1992) · PubMed · Cited by 104
A validated gRNA library for CRISPR/Cas9 targeting of the human glycosyltransferase genome
Narimatsu, Y., Joshi, H. J., Yang, Z., Gomes, C., Chen, Y., Lorenzetti, F. C., Furukawa, S., Schjoldager, K. T.-B. G., Hansen, L. H., Clausen, H., et al. (2017) · Glycobiology · doi:10.1093/glycob/cwx101 · Cited by 100
Self-citationPeiris, D., Spector, A. F., Lomax-Browne, H. J., Azimi, T., Ramesh, B., Loizidou, M., Welch, H., & Dwek, M. V. (2017) · Scientific Reports · doi:10.1038/srep43006 · Cited by 91
Sialyltransferase inhibition and recent advances
Wang, L., Liu, Y., Wu, L., & Sun, X. (2015) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2015.07.007 · Cited by 90
Antibody-Targeted Biodegradable Nanoparticles for Cancer Therapy
Shargh, V. H., Hondermarck, H., & Liang, M. (2015) · Nanomedicine · doi:10.2217/nnm.15.186 · Cited by 87
Temming, A. R., de Taeye, S. W., de Graaf, E. L., de Neef, L. A., Dekkers, G., Bruggeman, C. W., Koers, J., Ligthart, P. C., Nagelkerke, S. Q., Zimring, J. C., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900985 · Cited by 85
Potent Metabolic Sialylation Inhibitors Based on C-5-Modified Fluorinated Sialic Acids
Heise, T., Pijnenborg, J. F. A., Büll, C., van Hilten, N., Kers‐Rebel, E. D., Balneger, N., Elferink, H., Adema, G. J., & Boltje, T. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01757 · Cited by 82
Coussens, N. P., Braisted, J. C., Peryea, T., Sittampalam, G. S., Simeonov, A. M., & Hall, M. D. (2017) · Pharmacological Reviews · doi:10.1124/pr.117.013755 · Cited by 81
Movahedin, M., Brooks, T. M., Supekar, N. T., Gokanapudi, N., Boons, G., & Brooks, C. L. (2016) · Glycobiology · doi:10.1093/glycob/cww131 · Cited by 77
A Strategy to Discover Inhibitors of O-Linked Glycosylation
Gross, B. J., Swoboda, J. G., & Walker, S. (2007) · Journal of the American Chemical Society · doi:10.1021/ja078125s · Cited by 74
Small Molecule Inhibitors of Mucin-Type O-Linked Glycosylation from a Uridine-Based Library
Hang, H. C., Yu, C., Hagen, K. G. T., Tian, E., Winans, K. A., Tabak, L. A., & Bertozzi, C. R. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.02.023 · Cited by 73
Formulation/Preparation of Functionalized Nanoparticles for In Vivo Targeted Drug Delivery
Gu, F., Langer, R., & Farokhzad, O. C. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-483-4_37 · Cited by 56
Glycomimetic drugs--a new source of therapeutic opportunities.
Magnani, J. L., & Ernst, B. (2009) · PubMed · Cited by 54
Carcinoembryonic antigen carrying SLeX as a new biomarker of more aggressive gastric carcinomas
Gomes, C., Almeida, A., Barreira, A. C. S., Calheiros, J., Pinto, F., Abrantes, R., Costa, A. F., Polónia, A., Campos, D., Osório, H., et al. (2019) · Theranostics · doi:10.7150/thno.33858 · Cited by 51
Self-citationSong, L., & Linstedt, A. D. (2017) · eLife · doi:10.7554/elife.24051 · Cited by 42
Antibody and antibody derivatives as cancer therapeutics
Arlotta, K. J., & Owen, S. C. (2019) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1556 · Cited by 35
van Wijk, X. M., Lawrence, R., Thijssen, V. L., van den Broek, S. A. M. W., Troost, R., van Scherpenzeel, M., Naidu, N., Oosterhof, A., Griffioen, A. W., Lefeber, D. J., et al. (2015) · The FASEB Journal · doi:10.1096/fj.14-264226 · Cited by 30
Wittsten, A. H., & Roybal, K. T. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.09.005 · Cited by 29
High-Throughput “FP-Tag” Assay for the Identification of Glycosyltransferase Inhibitors
Gao, Z., Ovchinnikova, O. G., Huang, B.-S., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b10940 · Cited by 28
A solid-phase glycosyltransferase assay for high-throughput screening in drug discovery research
Donovan, R. S., Datti, A., Baek, M., Wu, Q., Sas, I. J., Korczak, B. M., Berger, E. G., Roy, R., & Dennis, J. W. (1999) · Glycoconjugate Journal · doi:10.1023/a:1007024916491 · Cited by 23
Miyashiro, M., Furuya, S., & Sugita, T. (2004) · Analytical Biochemistry · doi:10.1016/j.ab.2004.11.028 · Cited by 11
Cited by
Cox, T. R. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00329-7 · Cited by 976
Altered glycosylation in cancer: A promising target for biomarkers and therapeutics
Thomas, D., Rathinavel, A. K., & Radhakrishnan, P. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188464 · Cited by 372
Carbohydrate-based drugs launched during 2000−2021
Cao, X., Du, X., Jiao, H., An, Q., Chen, R., Fang, P., Wang, J., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.020 · Cited by 267
Unraveling the glycosylated immunopeptidome with HLA-Glyco
Bedran, G., Polasky, D. A., Hsiao, Y., Yu, F., da Veiga Leprevost, F., Alfaro, J. A., Cieslik, M., & Nesvizhskii, A. I. (2023) · Nature Communications · doi:10.1038/s41467-023-39270-2 · Cited by 15
Metadata
- Authors
- Costa, A. F., Campos, D., Reis, C. A., & Gomes, C.
- Venue
- Trends in Cancer
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 6
- Issue
- 9
- Pages
- 757-766
- ISSN
- 2405-8025 (ISSN-L)
- 2405-8033
- OpenAlex
- W3022878707
- Cited by
- 263
- References
- 55
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.